NMS-03305293

Phase 2Small molecule

NNerviano Medical Sciences

NMS-03305293 is one of 142 small molecule programs targeting Ovarian Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

141

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian CancerRecruiting

Small Cell Lung CancerRecruiting

GlioblastomaActive, not recruiting

Ovarian CancerPhase 1

Recruiting

Small Cell Lung CancerPhase 1

Recruiting

GlioblastomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

232 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

88 2

Gemzar

Johnson & Johnson

Phase 3

33 3

Pegylated Liposomal Doxorubicin

Merck & Co.

Phase 3

35 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

24 5

Imfinzi

AstraZeneca

Phase 3

8 6

Opdivo

Bristol-Myers Squibb

Phase 3

8 7

Adriamycin

Pfizer

Phase 3

8 8

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

23 9

Zepzelca

Jazz Pharmaceuticals

Phase 3

2 10

Nolvadex

AstraZeneca

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Small Cell Lung Cancer

NCT06931626

Q3 2027

Phase 1/2Active, not recruiting

Glioblastoma

NCT04910022

Phase 1Recruiting

Ovarian Cancer

NCT06930755

Clinical

Trials by Indication[1]

Glioblastoma1 trial

Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

Active, not recruiting·NNerviano Medical Sciences·Phase 1/2·NCT04910022·150 enrolled

Ovarian Cancer1 trial

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

Recruiting·NNerviano Medical Sciences·Phase 1·NCT06930755·24 enrolled

Advanced/Metastatic Solid Tumors1 trial

Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

Terminated·NNerviano Medical Sciences·Phase 1·NCT04182516·52 enrolled

Small Cell Lung Cancer1 trial

Study of NMS-03305293, a Non-Trapping PARP1-Specific PARP Inhibitor in Relapsed Small Cell Lung Cancer

Recruiting·NNerviano Medical Sciences·Phase 1·NCT06931626·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for NMS-03305293. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NMS-03305293 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NMS-03305293. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nerviano Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNerviano Medical Sciences

NMS-03305293

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Trials by Indication[1]

Glioblastoma1 trial

Ovarian Cancer1 trial

Advanced/Metastatic Solid Tumors1 trial

Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News